ClinicalTrials.gg

Program

KRAS G12D Inhibitor HRS-4642

Also written as “HRS-717 + HRS-4642+SHR-1316;”, “HRS-4642” and “HRS4642”.

In Jiangsu HengRui Medicine’s pipeline, KRAS G12D. Its studies are mostly in Pancreatic Neoplasms, led by Jiangsu HengRui Medicine.

Furthest: phase 3, since Nov 14, 20257 company-led studies, 7 open or runningNext primary completion: Feb 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine77 open or runningphase 3since Nov 14, 2025Sep 5, 2022Feb 2027phase 1 · NCT07906691
  • Named in Jiangsu HengRui Medicine’s own pipeline as HRS-4642, phase 3, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 5, 2022First study: phase 1 study in Advanced KRAS G12D Mutant Solid TumorsFirst studyNCT05533463 · 102 enrolled · China
  2. Jul 22, 2024Phase 2 study in Advanced Solid TumorsNCT06520488 · 118 planned · China
  3. Nov 14, 2025Phase 3 study in KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line SettingNCT07232875 · 588 planned · China
  4. Dec 9, 2025Phase 2 study in Locally Advanced or Metastatic Pancreatic Cancer WithNCT07296341 · 60 planned · China
  5. Sep 2, 2026Phase 2 study in Pancreatic NeoplasmsNCT07806058 · 140 planned · China
  6. Oct 22, 2026Phase 3 study in Systemic Treatment-naïve Pancreatic CancerNCT07900789 · 825 planned · China
  7. Oct 25, 2026Phase 1 study in Pancreatic NeoplasmsNCT07906691 · 18 planned · China

Ahead

  1. Feb 2027Primary completion: phase 1 study in Pancreatic NeoplasmsNCT07906691
  2. Mar 2027Primary completion: phase 2 study in Advanced Solid TumorsNCT06520488
  3. Oct 2027Primary completion: phase 2 study in Locally Advanced or Metastatic Pancreatic Cancer WithNCT07296341
  4. Dec 31, 2028Primary completion: phase 2 study in Pancreatic NeoplasmsNCT07806058

TargetBeta

“KRAS G12D”the company's pipeline, read by Claude · source
“An inhibitor of the oncogenic KRAS substitution mutation G12D, with potential antineoplastic activity. Upon administration, KRAS G12D inhibitor HRS-4642 specifically targets and binds to KRAS G12D. This prevents KRAS G12D-mediated signaling and activation of downstream survival pathways. This lea…”NCIt, read by Claude
“An inhibitor of the oncogenic KRAS substitution mutation G12D, ”NCIt, by rule

Other programs on KRAS

ProgramCompanyFurthest phaseStudies
sotorasibruleAmgenphase 328
adagrasibruleBristol-Myers Squibbphase 316
olomorasibEli Lillyphase 316
divarasibHoffmann-La Rochephase 313
KRAS G12D Inhibitor VS-7375ruleGenfleet Therapeutics (Shanghai)phase 312
glecirasibruleAllist Pharmaceuticalsphase 312
calderasibMerckphase 312
daraxonrasibruleRevolution Medicinesphase 310
garsorasibruleInventisBiophase 38
zoldonrasibruleRevolution Medicinesphase 36
HRS-7058Jiangsu HengRui Medicinephase 36
opnurasibruleNovartisphase 35

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07906691Pancreatic Neoplasms · China1Not yet recruitingFeb 202718
NCT07900789Systemic Treatment-naïve Pancreatic Cancer · China3Not yet recruitingNov 30, 2030825
NCT07806058Pancreatic Neoplasms · China2RecruitingDec 31, 2028140
NCT07296341Locally Advanced or Metastatic Pancreatic Cancer With · China2RecruitingOct 202760
NCT07232875KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting · China3RecruitingApr 2029588
NCT06520488Advanced Solid Tumors · China2RecruitingMar 2027118
NCT05533463Advanced KRAS G12D Mutant Solid Tumors · China1Active, not recruitingJun 25, 2024102

How it is read

Names in the registry

  • “HRS-717 + HRS-4642+SHR-1316;”, 3 entries
  • “HRS-4642”, 2 entries
  • “HRS4642”, 1 entry
  • “HRS -4642 + SHR-1316+ Gemcitabine Hydrochloride for Injection+Paclitaxel for Injection”, 1 entry
  • “HRS -4642 + Gemcitabine Hydrochloride for Injection+Paclitaxel for Injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.